| Paper | |
|---|---|
| Tenecteplase Thrombolysis for Acute Ischemic Stroke _____ A review of data from early trials evaluating the use of tenecteplase for acute ischemic stroke, up to and including the Extend-IA TNK trial. | LINK |
| (AcT) Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada: a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial _____ RCT comparing tenecteplase 0.25 mg/kg to alteplase 0.9 mg/kg in patients with acute ischemic stroke who are eligible for thrombolysis, finding tenecteplase to be non-inferior to alteplase for good functional outcomes at 90-120 days. | LINK |
| (NOR-TEST 2) Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway _____ RCT comparing tenecteplase 0.4 mg/kg to alteplase 0.9 mg/kg in patients with acute ischemic stroke who are eligible for thrombolysis and have a NIHSS >5. Enrollment was stopped early due to significantly more frequent ICH and higher mortality with tenecteplase use. Favorable functional outcomes were less frequent with tenecteplase. | LINK |
| (NOR-TEST) Tenecteplase versus alteplase for management of acute ischaemic stroke _____ RCT comparing tenecteplase 0.4 mg/kg to alteplase 0.9 mg/kg in patients with acute ischemic stroke who are eligible for thrombolysis or bridging therapy before thrombectomy, finding similar rates of favorable outcome and safety events in both groups, though median baseline NIHSS was only 4. | LINK |
| (EXTEND-IA TNK) Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke _____ RCT comparing tenecteplase 0.25 mg/kg to alteplase 0.9 mg/kg in patients with LVO who were eligible for both mechanical thrombectomy and thrombolysis within 4.5 hours, finding superior rates of reperfusion/recanalization and improved 90-day functional outcome with tenecteplase use. | LINK |